Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acid Suppression Therapy for Laryngomalacia
NCT04614974Phase 2Terminated
- Start
- Nov 2020
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of famotidine in gastroesophageal reflux disease (GERD). Started Nov 2020; status: terminated.
02
Drugs
famotidine
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT04614974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04614974.